Yes, S100 proteins are considered potential therapeutic targets due to their involvement in multiple pathological processes. Inhibiting specific S100 proteins could potentially disrupt their role in disease progression. For instance, targeting S100A4 could impede cancer metastasis, while modulating S100B activity might offer new avenues for treating neurodegenerative diseases.
